Skip to main content

Table 4 Stratified effects of metabolic syndrome on colon cancer and rectal cancer risks by VEGF 3′-UTR variants

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

    

CC risk

RC risk

Genotype/Haplotype

Model

Subgroup

Wild type

AOR (95% CI)

p

AOR (95% CI)

p

VEGF 1451C > T

Additive

Without MetS

CC

1.12 (0.80 - 1.54)

0.513

1.42 (0.99 - 2.03)

0.055

  

With MetS

CC

0.89 (0.50 - 1.59)

0.701

1.44 (0.77 - 2.67)

0.255

 

Dominant

Without MetS

CC

1.18 (0.79 - 1.77)

0.416

1.67 (1.07 - 2.61)

0.023

  

With MetS

CC

0.78 (0.41 - 1.49)

0.456

1.44 (0.74 - 2.78)

0.280

 

Recessive

Without MetS

CC

0.99 (0.41 - 2.40)

0.985

1.09 (0.41 - 2.87)

0.868

  

With MetS

CC

3.07 (0.30 - 31.00)

0.342

2.14 (0.13 - 35.71)

0.595

VEGF 1612G > A

Additive

Without MetS

GG

0.73 (0.49 - 1.07)

0.105

0.81 (0.53 - 1.24)

0.328

  

With MetS

GG

1.10 (0.61 - 2.02)

0.746

0.97 (0.50 - 1.87)

0.928

 

Dominant

Without MetS

GG

0.71 (0.46 - 1.09)

0.117

0.69 (0.42 - 1.14)

0.148

  

With MetS

GG

1.13 (0.60 - 2.14)

0.704

0.93 (0.46 - 1.89)

0.850

 

Recessive

Without MetS

GG

0.58 (0.15 - 2.17)

0.416

1.51 (0.49 - 4.61)

0.469

  

With MetS

GG

0.78 (0.05 - 13.40)

0.867

1.72 (0.10 - 28.53)

0.705

VEGF 1725G > A

Additive

Without MetS

GG

1.34 (0.72 - 2.49)

0.360

1.82 (0.95 - 3.48)

0.072

  

With MetS

GG

1.37 (0.62 - 2.98)

0.435

1.20 (0.51 - 2.85)

0.672

 

Dominant

Without MetS

GG

1.34 (0.72 - 2.49)

0.360

1.82 (0.95 - 3.48)

0.072

  

With MetS

GG

1.37 (0.62 - 2.98)

0.435

1.20 (0.51 - 2.85)

0.672

 

Recessive

Without MetS

GG

-

-

-

-

  

With MetS

GG

-

-

-

-

VEGF 1451C/1612G/1725G

 

Without MetS

Others

1.06 (0.80 - 1.40)

0.697

0.87 (0.63 - 1.19)

0.375

  

With MetS

Others

0.95 (0.61 - 1.49)

0.840

0.80 (0.50 - 1.28)

0.354

VEGF 1451T/1612G/1725G

 

Without MetS

Others

1.13 (0.80 - 1.58)

0.495

1.45 (1.00 - 2.09)

0.047

  

With MetS

Others

0.90 (0.51 - 1.58)

0.705

1.36 (0.77 - 2.42)

0.292

VEGF 1451C/1612A/1725G

 

Without MetS

Others

0.61 (0.38 - 0.97)

0.038

0.48 (0.26 - 0.86)

0.015

  

With MetS

Others

1.04 (0.48 - 2.25)

0.930

0.87 (0.37 - 2.08)

0.760

VEGF 1451C/1612A/1725A

 

Without MetS

Others

1.09 (0.58 - 2.05)

0.795

1.75 (0.93 - 3.28)

0.081

  

With MetS

Others

1.13 (0.53 - 2.43)

0.745

1.08 (0.47 - 2.51)

0.854

  1. Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). AORs and p values were adjusted by age and gender.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us